ClinicalTrials.gg
TerminatedNCT05255484Updated Oct 25, 2023

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

A Phase 1/2 interventional study of LM-108 and An Anti-PD-1 Antibody in Advanced Solid Tumor, sponsored by LaNova Medicines Limited. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by LaNova Medicines Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Completed primary objective.

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors

Read the detailed description

A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors

The study schedule includes screening visit (28 days prior to accept the investigational medicinal product (IMP)), treatment visit (accept IMP for the first time to the end of treatment (EOT)/early withdrawal), and follow-up visit (28 days after the EOT/early withdrawal).

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

LaNova Medicines Limited is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. (ECOG) performance status of 0-1
  2. Histological or cytological confirmation of recurrent or advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
  3. At least one for expansion cohorts per (RECIST) v1.1.
  4. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose

Key Exclusion Criteria:

  1. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤grade 1 of v5.0
  2. Uncontrolled tumour-related pain
  3. Known central nervous system (CNS)
  4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  5. Use of inhaled
  6. Known history of disease
  7. Use of any within 28 days
  8. Have severe cardiovascular disease
  9. Uncontrolled or severe illness
  10. History of immunodeficiency disease
  11. Active which are likely to require the treatment.
  12. female
  13. Have psychiatric illness or disorders

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LM-108 Dose Escalation

    Drug: LM-108 Administered intravenously

    Drug: LM-108

  • Experimental
    LM-108 Dose Expansion

    Drug: LM-108 Administered intravenously

    Drug: LM-108

  • Experimental
    LM-108 Combination Dose Escalation

    Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously

    Drug: LM-108 · Drug: An Anti-PD-1 Antibody

  • Experimental
    LM-108 Combination Dose Expansion

    Drug: LM-108 Administered intravenously Drug: An Anti-PD-1 Antibody Administered intravenously

    Drug: LM-108 · Drug: An Anti-PD-1 Antibody

Interventions

  • DrugLM-108

    Administered intravenously

  • DrugAn Anti-PD-1 Antibody

    Administered intravenously

This study also gives Pembrolizumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. AEs

    Incidence of adverse events

    Time frame: 126 weeks

  2. DLT

    Incidence of dose-limiting toxicity (DLT)

    Time frame: 21 days

  3. SAE

    Incidence of serious adverse event

    Time frame: 126 weeks

  4. Incidence of clinical significant in laboratory examinations

    Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.

    Time frame: 126 weeks

Secondary outcomes

  1. Incidence of anti-drug antibodies to LM-108

    Incidence of anti-drug antibodies to LM-108

    Time frame: 126 weeks

  2. Cmax

    Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax) for LM-108

    Time frame: 126 weeks

  3. Cmin

    PK Parameter: Minimum Observed Concentration (Cmin) for LM-108

    Time frame: 126 weeks

  4. Tmax

    PK Parameter: Time of Maximum Observed Concentration (Tmax) for LM-108

    Time frame: 126 weeks

  5. AUC

    PK Parameter: Area Under the Concentration-time Curve (AUC) for LM-108

    Time frame: 126 weeks

  6. Cmax,ss

    PK Parameter: Steady State Maximum Concentration (Cmax,ss)

    Time frame: 126 weeks

  7. Cmin, ss

    PK Parameter: Steady State Minimum Concentration (Cmin, ss)

    Time frame: 126 weeks

  8. CLss

    PK Parameter: Systemic Clearance at Steady State (CLss)

    Time frame: 126 weeks

  9. Rac

    PK Parameter: Accumulation Ratio (Rac)

    Time frame: 126 weeks

  10. t 1/2

    PK Parameter: Elimination Half-life (t 1/2)

    Time frame: 126 weeks

  11. Vss

    PK Parameter: Volume of Distribution at Steady-State (Vss)

    Time frame: 126 weeks

  12. DF

    PK Parameter: Degree of Fluctuation (DF)

    Time frame: 126 weeks

07

Study locations

6 sites
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
    Indianapolis, Indiana 46202, United States
  • Gabrail Cancer and Research Center
    Canton, Ohio 44718, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • University of Oklahoma
    Norman, Oklahoma 73104, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Oct 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Feb 24, 2022
StartActual
May 26, 2022
Primary completionActual
Oct 6, 2023
CompletionActual
Oct 6, 2023
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05255484
Responsible party
Sponsor
First posted
Feb 24, 2022
Start date
May 26, 2022
Primary completion
Oct 6, 2023
Completion
Oct 6, 2023
Last update
Oct 25, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cafelkibart

Start the discussion